Immune System Diseases Clinical Trial
— GvHD-ATOOfficial title:
Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
NCT number | NCT02966301 |
Other study ID # | GMED16-001 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | December 2016 |
Est. completion date | June 2020 |
Verified date | July 2020 |
Source | Medsenic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to evaluate the early chronic GvHD events (first line therapy), if the addition of arsenic trioxide to standard therapy with corticosteroids, with or without cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of corticosteroid therapy
Status | Completed |
Enrollment | 21 |
Est. completion date | June 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (=18 years) who have received a first allogeneic stem cell transplantation for a hematological disease (any source of hematopoietic stem cells is authorized; any category of conditioning regimen prior to allo-SCT is authorized; any type of stem cell donors is authorized) - Confirmed diagnosis of a first episode of chronic GvHD requiring systemic immunosuppressive therapy (any prior GvHD prophylaxis previously used is accepted). Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus. Chronic GvHD diagnosis will be based on the evaluation of the severity of the different clinical manifestations including: - Performance status evaluation - Cutaneous evaluation measured by the percentage of extension or the presence of sclerotic features. If relevant, confirmation with a biopsy should be performed whenever possible - Oral symptoms - Ocular symptoms - Gastro-intestinal symptoms - Evaluation of liver involvement (total bilirubin, transaminases and alkaline phosphatases) - Pulmonary function evaluation - Evaluation of the musculoskeletal manifestations, especially the amplitude of the relevant articulations - Genital tract symptoms - Signed informed consent - Absence of contra-indications to the use of ATO - Subjects affiliated with an appropriate social security system - Men must use a medically acceptable method of contraception throughout the treatment period and for at least 4 months and 10 days following the last treatment administration - Women who are of childbearing potential must have a negative serum pregnancy test and agree to use a medically acceptable method of contraception throughout the study and for 3 months following the end of the study - Patient not participating or not having participated in a clinical study in the 30 days prior to his/her inclusion in the study Exclusion Criteria: - Patient developing acute GvHD (whether early or "late onset" form) - Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus (presence of one or more acute GvHD manifestations in a patient with a diagnosis of chronic GvHD) - A "mild" form of chronic GvHD not requiring systemic immunosuppressive therapy - A "moderate" form of chronic GvHD limited to one organ site not requiring systemic immunosuppressive therapy - Patient receiving mycophenolate mofetil - Not the first episode of chronic GvHD needing systemic immunosuppressive therapy - Second allogeneic stem cell transplant - Severe cardiac diseases (congestive heart failure (NYHA class III), recent myocardial infarction (in the past 6 months before the inclusion), histories of unexplained syncope, ...) - Significant arrhythmias, electrocardiogram (EKG) abnormalities: - Congenital QT syndromes - History or presence of significant ventricular or atrial tachyarrhythmia - Clinically significant resting bradycardia (< 50 beats per minutes) - QTc>450msecformenand>470msecfor women on screening EKG (using the QTcF formula) - Right bundle branch block plus left anterior hemiblock, bifascicular block - Central or peripheral neuropathy - Neutrophils < 0.5 × 109/L - Platelets < 50 × 109/L - Potassium = 4 mEq/l* - Magnesium = 1.8 mg/dl* - Calcium = 2.15 mmol/l* - Hepatic impairment due to a suspected or proven liver damage, other than direct hepatic cGvHD involvement - PT < 50% - Renal impairment (creatinine = 100 µmol/l) - Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patients' death within 1 month after the start of therapy - Severe neurological or psychiatric disorders - Denied informed consent - Pregnancy - Women breastfeeding at selection and throughout the treatment period - If abnormal at selection, to be corrected and re-validated following electrolytes infusion, before inclusion and each drug perfusion. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medsenic |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide | Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus.
Response definition is as follows: Complete remission (CR) is defined as complete disappearance of any sign of chronic GvHD. Partial remission (PR) is defined as a significant improvement as defined by the organ or site specific measurement scale without progression in any other organ or site. |
six months | |
Secondary | Average Dose of Corticosteroids | Average dose in mg/kg/day of prednisone or prednisone equivalent | Average dose of Prednisone at 6 months after the first infusion of ATO | |
Secondary | Failure Free Survival | Treatment failure were defined by:
Initiation of a new systemic treatment for chronic GvHD; Recurrent or progressive malignancy; Death |
6 months after first ATO infusion | |
Secondary | Number of Adverse Events | Tolerability and safety of ATO in combination with Prednisone, with or without Ciclosporine, in patients with chronic GvHD after allo-SCT.
Adverse events follow-up for all patients throughout the study |
12 months after the first infusion of ATO for each patient | |
Secondary | Cumulative Incidence for Non-relapse Mortality (NRM) | Non-Relapse Mortality (NRM) of infectious and non-infectious origin | 12 months after first ATO infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02527187 -
Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
|
Phase 2 | |
Completed |
NCT01441076 -
Anakinra for Behcet s Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01472263 -
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
|
Phase 3 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Suspended |
NCT04642066 -
Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters
|
N/A | |
Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Completed |
NCT04103099 -
Impact of HLNatural Immune Supplement on Colds
|
N/A | |
Recruiting |
NCT03344094 -
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05445284 -
Group Education Trial to Improve Transition for Parents of Adolescents With T1D
|
N/A | |
Recruiting |
NCT06104111 -
Epigenetic Memory of Vitamin D Supplementation
|
Phase 1 | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Completed |
NCT01490177 -
Single Center Food Allergy Oral Immunotherapy Study
|
Phase 1 | |
Completed |
NCT01510626 -
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
|
Phase 1 | |
Completed |
NCT03922087 -
No-worry Baby Project
|